Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267189
Status:
COMPLETED
Last Update Posted:
2011-04-13
First Post:
2005-12-19
Brief Title:
RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A 6-month Multicenter Randomized Open-label Study of Safety and Efficacy of Everolimus-based Regimen Versus Calcineurin Inhibitor CNI-Based Regimen in Maintenance Liver Transplant Recipients
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess the effect of everolimus initiation together with reduction or discontinuation of calcineurin inhibitor CNI on renal function in maintenance liver transplant recipients with CNI-related renal impairment while maintaining efficacy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None